{"disease":{"id":"pneumococcal-immunization","name":"Pneumococcal Immunization","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":2},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pneumococcal-20-valent-conjugate-vaccine","indication_name":"Pneumococcal Immunization","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pneumococcal 20-valent conjugate vaccine","generic_name":"pneumococcal-20-valent-conjugate-vaccine","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be ","quality_score":null,"revenue":null,"mechanism":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be "}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06824194","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2360,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07348692","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2195,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06736041","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1714,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06975878","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1092,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04583618","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06760208","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","phase":"","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06824181","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":580,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06698198","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}